D’Angelo et al. reported a randomized study in unresponsive and metastatic patients with advanced sarcomas where they used nivolumab (anti-PD-1) alone or in combination with ipilimumab (anti-CTLA) [85]. This evidence concerns the gene PDCD1 and sarcoma.